Domov › Rak (vse vrste) › Tennessee › Nashville
Klinične študije za Rak (vse vrste) v Nashville, TN
65 študij za Rak (vse vrste) išče udeležence na lokacijah v Nashville in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 2/3
- SCRI Oncology Partners /ID# 276959, Nashville
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Vključevanje udeležencevFaza 2
- SCRI Oncology Partners /ID# 279733, Nashville
A Study of ASP3082 in Adults With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Vanderbilt University Medical Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Vključevanje udeležencevFaza 3
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- PHN-012-001 Site, Nashville
Registry Study for Radiation Therapy Outcomes
Vključevanje udeležencevOpazovalna študija
- Tennessee Oncology Proton Center, Franklin · 17 mi stran
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Vključevanje udeležencevOpazovalna študija
- Vanderbilt University Medical Center, Nashville
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- GSK Investigational Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Vključevanje udeležencevOpazovalna študija
- Vanderbilt University Medical Center, Nashville
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Vključevanje udeležencevFaza 2/3
- Henry-Joyce Cancer Clinic, Nashville
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Vključevanje udeležencevFaza 1
- Sarah Cannon Cancer Institute, Nashville
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Vključevanje udeležencevFaza 3
- Sarah Cannon Research Institute, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
Vključevanje udeležencevFaza 1
- SCRI Oncology Partners, Nashville
A Study of JNJ-87890387 for Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute, Nashville
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Vključevanje udeležencevFaza 3
- Vanderbilt University Medical Center, Nashville
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Vključevanje udeležencevFaza 3
- Quetzal Site 12, Nashville
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- SCRI Oncology Partners /ID# 279779, Nashville
- Vanderbilt University Medical Center /ID# 280169, Nashville
Pan Tumor Rollover Study
Vključevanje udeležencevFaza 2
- Tennesse Oncology, Nashville
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Vključevanje udeležencevFaza 3
- SCRI Oncology Partners ( Site 7000), Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Vključevanje udeležencevFaza 2
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institue, Nashville
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Vključevanje udeležencevFaza 2/3
- Sarah Cannon Research Inst, Nashville
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Vključevanje udeležencevFaza 1/2
- GSK Investigational Site, Nashville
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Vključevanje udeležencevFaza 1
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Center, Nashville
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Vključevanje udeležencevFaza 1/2
- SCRI Oncology Partners, Nashville
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Vključevanje udeležencevFaza 3
- Research Site, Nashville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Tennessee Oncology, Nashville
- USO - US Oncology Research Network, Nashville
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Vključevanje udeležencevOpazovalna študija
- Vanderbilt University, Nashville
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Vključevanje udeležencevFaza 3
- Tennessee Oncology PLLC - Chattanooga, Nashville
- Tennessee Oncology, PLLC, Nashville
- Vanderbilt University Medical Center, Nashville
Project: Every Child for Younger Patients With Cancer
Vključevanje udeležencevOpazovalna študija
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Vključevanje udeležencevFaza 3
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center at Franklin, Franklin · 17 mi stran
- in še 1
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- SCRI Oncology Partners, Nashville
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sara Cannon Research Institute Tennessee, Nashville
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Vključevanje udeležencevFaza 2
- SCRI Oncology Partners /ID# 274522, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Vključevanje udeležencevFaza 2
- Vanderbilt University, Ingram Cancer Center, Nashville
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Vključevanje udeležencevFaza 1/2
- Tennessee Oncology, Nashville
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Vključevanje udeležencevZgodnja faza 1
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
Vključevanje udeležencevFaza 1
- GSK Investigational Site, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Vključevanje udeležencevFaza 1
- Sarah Cannon, SCRI Oncology Partners, Nashville
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Vključevanje udeležencevFaza 1
- Context Investigational Site, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Vključevanje udeležencevFaza 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Vključevanje udeležencevFaza 1
- Research Site, Nashville
Galleri® in the Medicare Population.
Vključevanje udeležencevVabljeni zdravi prostovoljci
- HCA Healthcare Centennial, Nashville
- HCA Healthcare Nashville, Nashville
- HCA Healthcare Brentwood, Brentwood · 9 mi stran
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Vključevanje udeležencevFaza 1
- GSK Investigational Site, Nashville
Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
Vključevanje udeležencevFaza 1
- Vanderbilt University Medical Center, Nashville
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute, Nashville
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Vključevanje udeležencevZgodnja faza 1
- Vanderbilt University Medical Center, Nashville
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Vključevanje udeležencev
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Vključevanje udeležencevFaza 1
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- SCRI Oncology Partners, Nashville
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Vključevanje udeležencevFaza 2
- Tennessee Retina, PC, Nashville
A Study of YL242 in Subjects With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- US-205, Nashville
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Nashville
Inherited CAncer REgistry
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Vanderbilt-Ingram Cancer Center, Nashville
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Vključevanje udeležencevFaza 1/2
- SCRI Oncology Partners, Nashville
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Vključevanje udeležencevFaza 1/2
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
Vključevanje udeležencevOpazovalna študija
- Provision CARES Proton Therapy Nashville, Franklin · 17 mi stran
Študije za Rak (vse vrste) v drugih mestih
- Houston, TX121 študij
- New York City, NY109 študij
- Boston, MA85 študij
- Los Angeles, CA74 študij
- Philadelphia, PA59 študij
- Washington, DC58 študij
- Durham, NC58 študij
- Chicago, IL51 študij
- Atlanta, GA49 študij
- Seattle, WA49 študij
- Arlington, VA48 študij
- St. Louis, MO46 študij
Druge študije v Nashville
- Nemalicelični pljučni rak97 študij
- Rak dojke81 študij
- Metastatski rak70 študij
- Kolorektalni rak69 študij
- Rak jajčnikov49 študij
- Rak prostate43 študij
- Rak pljuč40 študij
- Ploščatocelični karcinom glave in vratu39 študij
- Rak trebušne slinavke39 študij
- Rak endometrija38 študij
- Melanom33 študij
- Množni mielom32 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.